
NuCana appoints GSK oncology head
pharmafile | December 2, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |Â Â GSK, Paolo Paoletti, biomed, nucanaÂ
Edinburgh-based clinical stage biopharma firm NuCana BioMed has appointed Dr Paolo Paoletti to its board of directors.
Paoletti has been president of Oncology at GSK since 2010, and started his career at the firm in 2004 as its head of development in this field. Prior to GSK he served as the vice president of clinical development for Lilly Oncology.
Hugh Griffith who is NuCana’s chief executive, says: “We are truly delighted to welcome Paolo to our board. His extensive clinical and commercial experience in oncology will be of enormous benefit to us as we refine our regulatory strategy and expand the clinical development programmes internationally.”
Paoletti adds: “I am delighted to join NuCana at this exciting time. I strongly believe that NuCana’s new medicines could have a major impact on the way we treat cancer patients in the future.”
Related Content

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis
GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …

Multiple myeloma treatment approved in Japan
GSK’s Blenrep (belantamab mafodotin) combinations have been approved by Japan’s Ministry of Health, Labour and …

US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit
PHILADELPHIA–GSK plc today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination …





